מדינה: ניו זילנד
שפה: אנגלית
מקור: Medsafe (Medicines Safety Authority)
Salbutamol 0.12%{relative} (as salbutamol sulphate)
Actavis New Zealand Limited
Salbutamol 0.12% w/v (as salbutamol sulphate)
2.5 mg/2.5mL
Solution for inhalation
Active: Salbutamol 0.12%{relative} (as salbutamol sulphate) Excipient: Sodium chloride Sulfuric acid Water for injection
Ampoule, plastic, 2.5 mL LDPE with twist off seal, packaged in strips of 10 with Al foil overwrap, 20 dose units
Prescription
Prescription
Sicor (Societa Italiana Corticosteroidi) Srl
Package - Contents - Shelf Life: Ampoule, plastic, 2.5 mL LDPE with twist off seal, packaged in strips of 10 with Al foil overwrap - 20 dose units - 2 years unopened stored at or below 25°C protect from light 3 months opened stored at or below 25°C protect from light - Ampoule, plastic, 2.5 mL LDPE with twist off seal, packaged in strips of 10 with Al foil overwrap - 30 dose units - 2 years unopened stored at or below 25°C protect from light 3 months opened stored at or below 25°C protect from light
2006-05-17
ARROW – SALBUTAMOL DESCRIPTION Salbutamol (as salbutamol sulfate). The chemical name for salbutamol sulfate 1-(4- hydroxy-3-hydroxymethylphenyl)-2-(t-butylamino)-ethanol sulfate. Its structural formula is: 2 (C 13 H 21 NO 3 ) 2 ,H 2 SO 4 Molecular weight: 576.7 CAS No.: 51022-70-9 Salbutamol sulfate is a white or almost white odourless powder. It is soluble in 4 parts of water, slightly soluble in 95% alcohol, in chloroform and solvent ether. Approximately 1.2mg of salbutamol sulfate is equivalent to 1 mg of salbutamol. PRESENTATION The inhalation is presented in ampoules containing a sterile, clear aqueous isotonic, preservative-free nebuliser solution for single use. Each ampoule of Arrow - Salbutamol ampoules 2.5 mg/2.5 mL contains salbutamol sulfate equivalent to 2.5 mg of salbutamol. Each ampoule of Arrow - Salbutamol 5 mg/2.5 mL contains salbutamol sulfate equivalent to 5mg of salbutamol. Each ampoule also contains the inactive ingredients sodium chloride and sulfuric acid in 2.5 mL. CLINICAL PARTICULARS _ACTIONS _ Salbutamol is a short-acting, relatively selective beta 2 -adrenoceptor agonist. Administration by inhalation results in direct stimulation of beta 2 -adrenoceptors in bronchial smooth muscle and hence bronchodilation. This is thought to be due to stimulation of adenyl cyclase by salbutamol, resulting in increased levels of cyclic AMP within cells. These are thought to inhibit the entry of calcium ions into the cells, thus inhibiting smooth muscle contraction. High levels of cyclic AMP in mast cells may also inhibit the release of histamine and slow reacting substance-A (SRS-A). After administration of salbutamol, stimulation of both beta 1 - and beta 2 -adrenoceptors o קרא את המסמך השלם